Exploring the lived experiences of pregnant women and community health care providers during the pandemic of COVID-19 in Bangladesh through a phenomenological analysis

Like many countries, the government of Bangladesh also imposed stay-at-home orders to restrict the spread of severe acute respiratory syndrome coronavirus-2 (COVID-19) in March, 2020. Epidemiological studies w...
Source: BMC Pregnancy and Childbirth - Category: OBGYN Authors: Tags: Research Source Type: research

Related Links:

NEW BRUNSWICK, N.J., January 6, 2022 – Johnson &Johnson (NYSE: JNJ) (the Company) today announced new results from the largest study to date on the durability of COVID-19 vaccines in the United States (U.S.), showing that a single shot of the Johnson &Johnson COVID-19 vaccine resulted in long-lasting protection for up to six months against COVID-19 breakthrough infections, hospitalizations, and intensive care unit (ICU) admissions. The study was sponsored by the Janssen Pharmaceutical Companies of Johnson &Johnson and conducted in partnership with the Department of Science-Aetion, Inc, and the Division of...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
There’s yet another colorful addition to the pandemic lexicon—“flurona”—but it doesn’t refer to a new variant or even a new condition. The made-up term describes simultaneous infection with both influenza and SARS-CoV-2, the virus that causes COVID-19. The two diseases do not combine to make some hybrid form of either virus, which makes “flurona” a bit of a fearmongering misnomer. But co-infection is becoming more common. Having COVID-19 and the flu at the same time has been a possibility since the beginning of the pandemic, but until now, rigorous safety precautions largely ...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news
Infect Disord Drug Targets. 2022 Jan 5. doi: 10.2174/1871526522666220105111358. Online ahead of print.ABSTRACTCoronavirus disease 2019 (COVID-19), which is a highly contagious viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had a catastrophic effect on the world's demographics, resulting in more than 3.8 million deaths worldwide, and establishing itself as the most serious global health crisis since the 1918 influenza pandemic. Several questions remain unanswered regarding the effects of COVID-19 disease during pregnancy. Although most infections are mild in high-risk population...
Source: Infectious Disorders Drug Targets - Category: Infectious Diseases Authors: Source Type: research
Exp Ther Med. 2022 Jan;23(1):102. doi: 10.3892/etm.2021.11025. Epub 2021 Dec 1.ABSTRACTSevere acute respiratory distress syndrome with coronavirus 2 (SARS-CoV-2) infection affected pregnant women during the pandemic. Immunological particularity of this population and the increased need for medical assistance placed this population in a high-risk category for SARS-Cov-2 infection. Owing to high contamination risk and limited studies regarding vertical transmission, the labor and delivery of positive women required particular conditions. Cesarean section probably proved to be the optimal option for delivery of infants to red...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Authors: Source Type: research
NEW BRUNSWICK, N.J., December 30, 2021 – Johnson &Johnson (NYSE: JNJ) (the Company) today announced new preliminary results from the South African Phase 3b Sisonke study which showed that a homologous (same vaccine) booster shot of the Johnson &Johnson COVID-19 vaccine (Ad26.COV2.S) demonstrated 85 percent effectiveness against COVID-19-related hospitalization. The study, conducted by the South African Medical Research Council (SAMRC), showed that the Johnson &Johnson booster reduced the risk of hospitalization from COVID-19 among healthcare workers in South Africa after Omicron became the dominant varian...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
CONCLUSION: COVID-19 is a new disease that has become a pandemic. This disease should be watched out for because transmission is relatively fast, has a mortality rate that cannot be ignored, and there is no definitive therapy. There are still many knowledge gaps in this field, so further studies are needed.PMID:34929907 | DOI:10.1016/j.gaceta.2021.10.089
Source: Gaceta Sanitaria - Category: International Medicine & Public Health Authors: Source Type: research
NEW BRUNSWICK, N.J., December 16, 2021 – Johnson &Johnson remains confident in the overall positive benefit-risk profile of its COVID-19 vaccine. Studies have shown that the Johnson &Johnson COVID-19 vaccine generates strong antibody and cellular immune responses [i] and long-lasting immune memory[ii] and breadth of protection across variants. In addition, a growing body of evidence is revealing the strength of protection of our vaccine as a booster to either the Janssen COVID-19 vaccine or a different authorized or approved COVID-19 vaccine, both in terms of its efficacy and durability.[iii], [iv], [v], [vi]...
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
Until September 2021, the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2; COVID-19) pandemic caused over 217 million infections and over 4.5 million deaths. In pregnant women the risk factors for the need of intensive care treatment are generally the same as in the overall population. Of note, COVID-19+ women deliver earlier than COVID-19- women, and the risk for severe neonatal and perinatal morbidity and mortality is significantly higher. The probability and pathways of vertical transmission of the virus from the pregnant woman to the fetus are highly controversial. Recent data have shown that 54 (13%) of 41...
Source: Cells Tissues Organs - Category: Cytology Source Type: research
NEW BRUNSWICK, N.J., December 15, 2021 – Johnson &Johnson (NYSE: JNJ) (the Company) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a Positive Opinion for use of the Company’s COVID-19 vaccine as a booster for adults aged 18 and older at least two months after primary vaccination with a single-shot of the Johnson &Johnson COVID-19 vaccine, and as a ‘mix and match’ booster following primary vaccination with an approved two-shot mRNA COVID-19 vaccine regimen (known as heterologous boosting). “We are pleased with...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
CONCLUSION: It is extremely vital to care for women's mental health during pregnancy and after childbirth during these unprecedented times. This review urges the need to design adequate interventions for this vulnerable population to prevent negative consequences of PPD.PMID:34894838 | DOI:10.1177/21501327211059348
Source: Primary Care - Category: Primary Care Authors: Source Type: research
More News: Bangladesh Health | Coronavirus | COVID-19 | Epidemiology | Government | Health Management | OBGYN | Pandemics | Pregnancy | Respiratory Medicine | SARS | Study | Women